OTCMKTS:SNPHY Santen Pharmaceutical Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $7.85 +0.04 (+0.51%) (As of 07/1/2022 03:56 PM ET) Add Compare Share Today's Range$7.67▼$7.9050-Day Range$7.22▼$8.7952-Week Range$7.06▼$15.70Volume39,792 shsAverage Volume113,149 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest Santen Pharmaceutical Stock Forecast (MarketRank)Analyst RatingN/AUpside/DownsideN/AShort InterestHealthyDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.56 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Santen Pharmaceutical. Previous Next 4.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Santen Pharmaceutical has recently decreased by 90.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSanten Pharmaceutical does not currently pay a dividend.Dividend GrowthSanten Pharmaceutical does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNPHY. Previous Next 2.8 News and Social Media Coverage News SentimentSanten Pharmaceutical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Santen Pharmaceutical this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address About Santen PharmaceuticalSanten Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.Read More SNPHY Stock News HeadlinesJune 11, 2022 | americanbankingnews.comShort Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Declines By 63.3%May 24, 2022 | marketwatch.comOphthalmology Equipment Market Demand, Opportunity, Outlook, Trends, Revenue, Future Growth Opportunities By2029November 11, 2021 | seekingalpha.comSanten Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call PresentationMay 19, 2021 | finance.yahoo.comGlaukos Inks New Agreement With Santen; Street Sees 23.8% UpsideMay 12, 2021 | seekingalpha.comSanten Pharmaceutical Co., Ltd. 2021 Q4 - Results - Earnings Call PresentationMay 12, 2021 | seekingalpha.comSanten Pharmaceutical Co., Ltd. reports FY resultsMarch 31, 2021 | marketwatch.comOphthalmology Equipment Market Size, Growth, Trends | Global Report 2029January 21, 2021 | bloomberg.comSanten Pharmaceutical Co LtdNovember 20, 2020 | wsj.comSanten Pharmaceutical Co. Ltd. ADROctober 18, 2020 | nasdaq.comSanten Pharmaceutical Co. Ltd. ADR (SNPHY)June 30, 2020 | feeds.benzinga.comSanten and Singapore's Health-tech Start-up, Plano Form a Strategic Alliance to Tackle the Global Burden of MyopiaFebruary 20, 2020 | www.benzinga.comTRACON to Report Fourth Quarter and Full Year 2019 Financial Results and Company Highlights on February 27, 2020See More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers-General Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SNPHY CUSIPN/A CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,229Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Santen Pharmaceutical Frequently Asked Questions Should I buy or sell Santen Pharmaceutical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Santen Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Santen Pharmaceutical stock. View analyst ratings for Santen Pharmaceutical or view top-rated stocks. How has Santen Pharmaceutical's stock performed in 2022? Santen Pharmaceutical's stock was trading at $12.18 at the beginning of 2022. Since then, SNPHY shares have decreased by 35.6% and is now trading at $7.85. View the best growth stocks for 2022 here. Are investors shorting Santen Pharmaceutical? Santen Pharmaceutical saw a decline in short interest in June. As of June 15th, there was short interest totaling 400 shares, a decline of 90.9% from the May 31st total of 4,400 shares. Based on an average trading volume of 313,600 shares, the days-to-cover ratio is presently 0.0 days. View Santen Pharmaceutical's Short Interest. Who are Santen Pharmaceutical's key executives? Santen Pharmaceutical's management team includes the following people: Mr. Shigeo Taniuchi, Pres, CEO & Representative Director (Age 49, Pay $779.23k)Mr. Kazuo Koshiji, Chief Financial Officer & Chief Risk OfficerMr. Minori Hara, Chief Digital & Information OfficerMs. Kaori Itagaki, Gen. Mang. of Investor Relations GroupMs. Mika Masunari, Gen. Counsel & Chief Compliance OfficerMs. Nobuko Kato, Chief Communications OfficerMr. Satoshi Suzuki, Sr. Corp. Officer & Head of Corp. Devel. DivisionMr. Shinichi Teramachi, Corp. Officer, Head of Sales Department & Japan Sales and Marketing DivisionMr. Ippei Kurihara, Corp. Officer, Head of Marketing Department & Japan Sales and Marketing DivisionMr. Tomo Yashiki, Corp. Officer & Head of HR Division Who are some of Santen Pharmaceutical's key competitors? Some companies that are related to Santen Pharmaceutical include Cosmo Pharmaceuticals (CMOPF), JCR Pharmaceuticals (JCRRF), Kyowa Kirin (KYKOF), Orion Oyj (ORINF) and PT Kalbe Farma Tbk. (PTKFF). View all of SNPHY's competitors. What is Santen Pharmaceutical's stock symbol? Santen Pharmaceutical trades on the OTCMKTS under the ticker symbol "SNPHY." How do I buy shares of Santen Pharmaceutical? Shares of SNPHY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Santen Pharmaceutical's stock price today? One share of SNPHY stock can currently be purchased for approximately $7.85. How many employees does Santen Pharmaceutical have? Santen Pharmaceutical employs 4,229 workers across the globe. How can I contact Santen Pharmaceutical? Santen Pharmaceutical's mailing address is Kita-ku, Osaka Shi, Osaka Fu 530-8552. The official website for Santen Pharmaceutical is www.santen.com. The company can be reached via phone at (167) 664-8621. This page (OTCMKTS:SNPHY) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
